Scoop: Roche-backed start­up gives up on CD47, lays off all em­ploy­ees

Arch On­col­o­gy end­ed its work on de­vel­op­ing an an­ti-CD47 an­ti­body and most em­ploy­ees have left the com­pa­ny, End­points News has learned.

The Bris­bane, CA, and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER